Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Transitional Cell Carcinoma

Explore clinical trials studying Fallopian Tube Transitional Cell Carcinoma. Study availability and eligibility vary by location and protocol.

16 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Fallopian Tube Transitional Cell Carcinoma trial results

Recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

NCT04575935

Conditions
Adnexal Diseases, Advanced Ovarian Carcinoma, Endocrine Gland Neoplasms, +39 more
Locations
  • University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States
  • Cleveland Clinic Foundation - Florida Weston, Florida, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View all 19 locations
View Trial Details
Completed

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00951496

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine System Diseases, +55 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
View all 503 locations
View Trial Details
Completed

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02020707

Conditions
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, +45 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details
Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT01097746

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +48 more
Locations
  • M D Anderson Cancer Center Houston, Texas, United States
  • MD Anderson Regional Care Center-Katy Houston, Texas, United States
  • MD Anderson Regional Care Center-Bay Area Nassau Bay, Texas, United States
  • MD Anderson Regional Care Center-Sugar Land Sugar Land, Texas, United States
View Trial Details
Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00888615

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +39 more
Locations
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • John Muir Medical Center-Concord Campus Concord, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California San Diego San Diego, California, United States
View all 163 locations
View Trial Details
Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00989651

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +59 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View all 23 locations
View Trial Details
Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01074411

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +41 more
Locations
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 14 locations
View Trial Details
Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00262847

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +48 more
Locations
  • Northeast Alabama Regional Medical Center Anniston, Alabama, United States
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
View all 632 locations
View Trial Details
Active, Not Recruiting

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
Locations
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
View Trial Details

Related conditions